Trillium Asset Management LLC Sells 16,829 Shares of Merit Medical Systems, Inc. $MMSI

Trillium Asset Management LLC decreased its position in Merit Medical Systems, Inc. (NASDAQ:MMSI) by 16.1% in the fourth quarter, Holdings Channel reports. The firm owned 87,721 shares of the medical instruments supplier’s stock after selling 16,829 shares during the period. Trillium Asset Management LLC’s holdings in Merit Medical Systems were worth $8,033,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of MMSI. AQR Capital Management LLC boosted its holdings in shares of Merit Medical Systems by 7.3% in the first quarter. AQR Capital Management LLC now owns 16,361 shares of the medical instruments supplier’s stock valued at $1,730,000 after purchasing an additional 1,114 shares during the period. Goldman Sachs Group Inc. lifted its holdings in Merit Medical Systems by 16.9% during the first quarter. Goldman Sachs Group Inc. now owns 719,313 shares of the medical instruments supplier’s stock worth $76,039,000 after buying an additional 103,878 shares during the period. EverSource Wealth Advisors LLC lifted its holdings in Merit Medical Systems by 745.9% during the second quarter. EverSource Wealth Advisors LLC now owns 922 shares of the medical instruments supplier’s stock worth $86,000 after buying an additional 813 shares during the period. First Trust Advisors LP lifted its holdings in Merit Medical Systems by 24.8% during the second quarter. First Trust Advisors LP now owns 59,215 shares of the medical instruments supplier’s stock worth $5,535,000 after buying an additional 11,770 shares during the period. Finally, Cerity Partners LLC lifted its holdings in Merit Medical Systems by 9.1% during the second quarter. Cerity Partners LLC now owns 3,019 shares of the medical instruments supplier’s stock worth $282,000 after buying an additional 251 shares during the period. Hedge funds and other institutional investors own 99.66% of the company’s stock.

Analyst Ratings Changes

A number of analysts have weighed in on the company. Compass Point set a $107.00 target price on Merit Medical Systems in a report on Monday, April 20th. Wall Street Zen lowered Merit Medical Systems from a “strong-buy” rating to a “buy” rating in a report on Sunday, April 5th. Citigroup restated an “outperform” rating on shares of Merit Medical Systems in a report on Monday, April 20th. JPMorgan Chase & Co. lowered their target price on Merit Medical Systems from $95.00 to $77.00 and set an “overweight” rating for the company in a report on Friday, May 1st. Finally, Piper Sandler lowered their target price on Merit Medical Systems from $106.00 to $96.00 and set an “overweight” rating for the company in a report on Friday, April 17th. Eight research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $92.80.

Merit Medical Systems Stock Performance

Shares of MMSI stock opened at $66.53 on Friday. The business’s fifty day simple moving average is $65.56 and its 200-day simple moving average is $75.42. The company has a market cap of $3.97 billion, a PE ratio of 28.80, a PEG ratio of 2.08 and a beta of 0.54. The company has a current ratio of 5.08, a quick ratio of 3.46 and a debt-to-equity ratio of 0.45. Merit Medical Systems, Inc. has a 12-month low of $59.74 and a 12-month high of $96.74.

Merit Medical Systems (NASDAQ:MMSI) last issued its quarterly earnings results on Thursday, April 30th. The medical instruments supplier reported $0.94 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.84 by $0.10. The business had revenue of $381.88 million for the quarter, compared to the consensus estimate of $377.59 million. Merit Medical Systems had a return on equity of 13.54% and a net margin of 9.03%.The business’s quarterly revenue was up 7.4% on a year-over-year basis. During the same period in the prior year, the firm posted $0.86 earnings per share. Merit Medical Systems has set its FY 2026 guidance at 4.010-4.150 EPS. Analysts expect that Merit Medical Systems, Inc. will post 3.62 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Merit Medical Systems news, insider Brian G. Lloyd purchased 2,000 shares of Merit Medical Systems stock in a transaction dated Thursday, May 7th. The shares were acquired at an average cost of $62.62 per share, with a total value of $125,240.00. Following the completion of the transaction, the insider owned 2,000 shares in the company, valued at approximately $125,240. This trade represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Lynne N. Ward sold 5,000 shares of the company’s stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $62.61, for a total value of $313,050.00. Following the transaction, the director directly owned 7,809 shares in the company, valued at approximately $488,921.49. The trade was a 39.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 0.70% of the company’s stock.

Merit Medical Systems Profile

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.